FIG 1.

Efficacy of PVP-I formulations and Bactroban Nasal against MRSA infection in an ex vivo PVM model. (a) Schematic of experimental design. (b) Explants of normal PVM were infected with S. aureus Xen30, treated, washed with sterile PBS containing 2% mucin and then incubated as shown in panel a. The explants were treated with Betadine Ophthalmic, 3M SNP, or Bactroban Nasal (B. Nasal) or left untreated as a control. Following incubation for 1, 6, or 12 h, explants were transferred to a neutralization buffer containing sodium thiosulfate and vortex mixed to release surviving bacteria. Serial dilutions were made in sterile PBS and plated onto tryptic soy agar supplemented with sheep blood, using a spiral plater. The number of viable bacterial cells is expressed as log₁₀ CFU/explants recovered over time. Values are means ± SEMs (error bars). Values that are statistically significantly different (P < 0.05) from the value for the untreated control are indicated by an asterisk.